Cipla LtdNSE: CIPLA

Press Release Dec 30 2022

· Issued by Cipla Ltd

Filed with NSE · · 3 pages · English

Summary by 6ix AI

This partnership aims to develop mRNA-based therapies, particularly for respiratory diseases, and enhance access to innovative treatments in emerging markets. The transaction is expected to complete within a specified timeframe, pending regulatory approvals. Umang Vohra, Cipla's CEO, emphasized the significance of this collaboration in advancing their innovation journey in healthcare solutions.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Cipla Ltd on 6ix

Earlier from Cipla

Later from Cipla

All Cipla news releases